EUCTR2015-000584-14-Outside-EU/EEA
Active, not recruiting
Not Applicable
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naïve CRIM(-) Patients with Infantile-Onset Pompe Disease
Genzyme Corporation Inc0 sites4 target enrollmentApril 15, 2015
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pompe disease (acid alpha-glucosidase deficiency)
- Sponsor
- Genzyme Corporation Inc
- Enrollment
- 4
- Status
- Active, not recruiting
- Last Updated
- 10 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The patient's legal guardian(s) must have provided written informed consent prior to any study\-related procedures being performed
- •The patient must have had a clinical diagnosis of Pompe disease as defined by documented acid alpha\-glucosidase (GAA) deficiency (deficient endogenous GAA activity) in skin fibroblasts, muscle, or blood, or 2 GAA mutations. Consent was also sought from the biological parent(s) for parental GAA mutational analysis, but was not a requirement for study eligibility
- •The patient must have not received Myozyme® or any rhGAA therapies prior to enrollment in the study
- •The patient must be CRIM negative via Western Blot analysis performed on skin fibroblasts or via 2 known CRIM negative mutations (in which case CRIM status was to be confirmed by Western Blot analysis after enrollment)
- •The patient's legal guardian(s) must have the ability to comply with the clinical protocol
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 4
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
Exclusion Criteria
- •The patient had any medical condition that, in the opinion of the Investigator, could be exacerbated/precipitated by or interfere with the study regimen or assessments; such conditions may include but were not limited to human immunodeficiency virus, cancer, Hepatitis B, Hepatitis C, Cytomegalovirus, Herpes Simplex, John Cunningham (JC) virus, Parvovirus, or Epstein Barr virus or tuberculosis
- •The patient had used any investigational product within 30 days prior to study enrollment
- •The patient had or was required to have any live vaccination within 1 month prior to enrollment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Immune Tolerance Induction StudyPompe disease (acid alpha-glucosidase deficiency)MedDRA version: 17.1Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2015-000583-34-Outside-EU/EEAGenzyme Corporation Inc9
Active, not recruiting
Phase 1
An Exploratory Study of the Safety and Efficacy of BOTOX® for the Treatment of Premature EjaculatioPremature EjaculationMedDRA version: 14.1 Level: PT Classification code 10036596 Term: Premature ejaculation System Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]EUCTR2013-001650-94-GBAllergan Limited59
Recruiting
Not Applicable
A exploratory study of the efficacy and safety of oxaliplatin in combination with S-1 in the treatment of non-resectable gastric cancernon-resectable gastric cancer or reccurent gastric cancerJPRN-UMIN000002463niversity of Tokyo Hospital20
Recruiting
Not Applicable
An exploratory study on the efficacy and safety of Hangesyasinto (TJ-14) for DCF chemotherapy or DCF-RT chemoradiotherapy induced diarrhea in the patients with advanced esophageal cancer.JPRN-UMIN000023825Dokkyo Medical University24
Completed
Not Applicable
An exploratory study of the efficacy and safety of yokukansan for postoperative delirium in patients who underwent surgical resection of malignant tumor of digestive system.Digestive system cancerJPRN-UMIN000013235Hitachi,Ltd.,Hitachi General Hospital40